Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Having lost the race to the Moon, the USSR seemed to decide to concentrate on orbital space stations instead of pursuing a crewed lunar mission. During 1969 and 1970, they launched six more Soyuz flights after Soyuz 3 and then launched a series of six successful space stations (plus two failures to achieve orbit and one station rendered uninhabitable due to damage from explosion of the launcher's upper stage) on their Proton-K heavy-lift launcher in their Salyut program designed by Kerim Kerimov. Each one weighed between 18,500 and 19,824 kilograms (40,786 and 43,704 lb), was 20 meters (66 ft) long by 4 meters (13 ft) in diameter, and had a habitable volume of 99 cubic meters (3,500 ft3). All of the Salyuts were presented to the public as non-military scientific laboratories, but three of them were covers for military Almaz reconnaissance stations: Salyut 2 (failed), Salyut 3, and Salyut 5.
The hormonal IUD is a small T-shaped piece of plastic, which contains levonorgestrel, a type of progestin. The cylinder of the device is coated with a membrane that regulates the release of the drug. Bayer markets Skyla as Jaydess in the United Kingdom. Jaydess releases six micrograms per day and lasts for three years. In comparison, oral contraceptives can contain 150 micrograms of levonorgestrel. The hormonal IUD releases the levonorgestrel directly into the uterus, as such its effects are mostly paracrine rather than systemic. Most of the drug stays inside the uterus, and only a small amount is absorbed into the rest of the body.
=== Switzerland === In Switzerland, the sale and production of absinthe was prohibited from 1910 to 1 March 2005. This was based on a vote in 1908, inspired by the Jean Lanfray incident. To be legally made or sold in Switzerland, absinthe must be distilled, must not contain certain additives, and must be either naturally coloured or left uncoloured. In 2014, the Federal Administrative Court of Switzerland invalidated a governmental decision of 2010 which allowed only absinthe made in the Val-de-Travers region to be labelled as absinthe in Switzerland. The court found that absinthe was a label for a product and was not tied to a geographic origin.
== Regulation == Insofar as both IAPP and insulin are produced by the pancreatic β-cells, impaired β-cell function (due to lipotoxicity and glucotoxicity) will affect both insulin and IAPP production and release. Insulin and IAPP are regulated by similar factors since they share a common regulatory promoter motif. The IAPP promoter is also activated by stimuli which do not affect insulin, such as tumor necrosis factor alpha and fatty acids. One of the defining features of Type 2 diabetes is insulin resistance. This is a condition wherein the body is unable to utilize insulin effectively, resulting in increased insulin production; since proinsulin and proIAPP are cosecreted, this results in an increase in the production of proIAPP as well. Although little is known about IAPP regulation, its connection to insulin indicates that regulatory mechanisms that affect insulin also affect IAPP. Thus blood glucose levels play an important role in regulation of proIAPP synthesis.
As an antifungal, ketoconazole is structurally similar to imidazole, and interferes with the fungal synthesis of ergosterol, a constituent of fungal cell membranes, as well as certain enzymes. As with all azole antifungal agents, ketoconazole works principally by inhibiting the enzyme cytochrome P450 14α-demethylase (CYP51A1). This enzyme participates in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. Lower doses of fluconazole and itraconazole are required to kill fungi compared to ketoconazole, as they have been found to have a greater affinity for fungal cell membranes. Resistance to ketoconazole has been observed in a number of clinical fungal isolates, including Candida albicans. Experimentally, resistance usually arises as a result of mutations in the sterol biosynthesis pathway. Defects in the sterol 5-6 desaturase enzyme reduce the toxic effects of azole inhibition of the 14-alpha demethylation step. Multidrug-resistance (MDR) genes can also play a role in reducing cellular levels of the drug. As azole antifungals all act at the same point in the sterol pathway, resistant isolates are normally cross-resistant to all members of the azole family.
Sources: en.wikipedia.org
Pretzelmaker is a chain of independently owned and operated franchised stores that specialize in hand-rolled pretzels, smoothies and cold beverages. It is a franchise brand in the portfolio of Global Franchise Group. It has 86 locations in the U.S.
=== As a drug target === The YAP1 oncogene serves as a target for the development of new cancer drugs. Small compounds have been identified that disrupt the YAP1-TEAD complex or block the binding function of WW domains. These small molecules represent lead compounds for the development of therapies for cancer patients, who harbor amplified or overexpressed YAP oncogene.
== Diagnosis == The diagnosis of cholecystitis is suggested by the history (abdominal pain, nausea, vomiting, fever) and physical examinations in addition to laboratory and ultrasonographic testing. Boas's sign, which is pain in the area below the right scapula, can be a symptom of acute cholecystitis.
=== Geological applications === NanoSIMS has also proved useful in studying cosmochemical issues, where samples of single, micro- or sub-micrometer-sized grains from meteorites as well as microtome sections prepared by the focused ion beam (FIB) technique can be analyzed. NanoSIMS can be combined with transmission electron microscopy (TEM) when using microtome or FIB sections. This combination allows for correlated mineralogical and isotopic studies in situ at a sub-micrometer scale. It is particularly useful in materials research because of its high sensitivity at high mass resolution, which allow for trace element imaging and quantification.
== Medication compliance == Medication compliance is defined as the degree to which the patient follows the therapy that is recommended by healthcare professionals. There are direct and indirect methods to evaluate compliance. Direct method refers to the measurement that the healthcare professionals observed or measure the patient's drug-taking behavior. Indirect method refers to the healthcare professionals do not observe or measure the drug-taking behavior of the patient but use the other source of information to evaluate the compliance. The direct method includes measurement of drug (or the corresponding metabolite) concentration, while the indirect method includes pill counting and the self-report from the patient. The direct method is more time-consuming, more expensive, more invasive, but it is more accurate. The indirect method has a lower accuracy but is easier to administer to the patient. If the patient fails to comply with treatment, for example, by not taking the medication according to the instructions, it leads to risk and a poor treatment outcome.
Sources: en.wikipedia.org
== Regulatory scrutiny == In September 2022, Pilot launched a controversial advertising campaign taking aim at R U OK? day. Large billboards with R U OK?'s corporate branding criticised the mental health awareness initiative for making conversation rather than taking action. The campaign received criticism for appearing as a marketing effort disguised as mental health advocacy, with critics noting the company's treatment model focuses on pharmaceutical prescriptions rather than counselling services. In 2023, TV station Seven featured a story about former AFL player and Pilot ambassador Dale Thomas on its news bulletin. Pilot received criticism about the story presenting more like an informercial. ABC TV's Media Watch featured Eucalyptus and Pilot to further highlight the paid partnership and lack of reporting on the upcoming regulator crackdowns. Pilot later turned the news bulletin into an ad on Facebook and Instagram. In 2024, Pilot's TV ad for an erectile dysfunction treatment received 35 complaints for concerns of sexual innuendo to Ad Standards. The Ad Standard Community Panel assessed whether the ad breached the advertising rules and determined no breach. In 2025, the same ad received 32 complaints with the same outcome. In 2025, Pilot received backlash for their Father's Day campaign, which encouraged its Instagram followers to "gift" their father the company's erectile dysfunction treatments instead of a more traditional gift.
==== Colourants and pigments ==== In addition to the uses described above, the European Union Observatory for Nanomaterials (EUON) has highlighted that silver nanoparticles are used in colourants in cosmetics, as well as pigments. A recently published study by the EUON has illustrated the existence of knowledge gaps regarding the safety of nanoparticles in pigments.
Partly to aid the Apollo missions, the Surveyor program was conducted by NASA, with five successful soft landings out of seven attempts from 1966 to 1968. The Lunar Orbiter program had five successes out of five attempts in 1966–1967. In late 1966, Luna 13 became the third spacecraft to make a soft-landing on the Moon, with the American Surveyor 1 having now taken second. Luna 13 made use of inflatable air-bags to soften it's landing. Surveyor 1 was a 995 kg lander, notably larger than the 112 kg Luna 13 E-6M lander. Surveyor 1 was equipped with a Doppler velocity sensing system that fed information into the spacecraft computer to implement a controllable descent to the surface. Each of the three landing pads also carried aircraft-type shock absorbers and strain gauges to provide data on landing characteristics, important for future Apollo missions. Surveyor 3, which successfully touched down on the Moon April 20, 1967, carried a 'surface sampler' which facilitated tests of the Lunar soil. Based on these experiments, scientists concluded that lunar soil had a consistency similar to wet sand, with a bearing strength of about 10 pounds per square inch (0.7 kilograms per square centimeter, or 98 kilopascals), which was concluded to be solid enough to support an Apollo Lunar Module. The Surveyor 3 lander would be later visited by Apollo 12 astronauts. On Nov. 17, 1967, before mission termination, Surveyor 6 fired its thrusters for 2.5 seconds, becoming the first spacecraft launched from the lunar surface.
Even after the 1947 partition, the Muslims from India kept migrating to Pakistan, especially Karachi and Sindh province. Wars in neighbouring Afghanistan in the 1980s and 1990s pushed millions of Afghan refugees into Pakistan, mainly in Khyber-Pakhtunkhwa and tribal areas, with some in Karachi and Quetta. Pakistan hosts one of the world's largest refugee populations. Additionally, around 2 million Bengalis and half a million undocumented individuals, purportedly from Myanmar, reside in Pakistan. Pakistan ordered the mass expulsion of undocumented Afghans in October 2023, citing national security risks. Migration of Bengalis and Rohingya to Pakistan started in the 1980s and continued till 1998. Karachi hosts a significant number of Bengali settlements, and large Rohingya migration made it one of their largest populations outside Myanmar. Karachi's Burmese community resides in various slums across the city. According to BBC, thousands of Uyghur Muslims live in Gilgit-Baltistan, some left Xinjiang, China and the thriving trading town of Kashgar in 1949, while others are later arrivals, claiming to escape political oppression. Since 1989, thousands of Kashmiri Muslim refugees fled to Pakistan, alleging rape and forced displacement by Indian soldiers.
Nonbenzodiazepines (Z-drugs) are a class of psychoactive drugs that are "benzodiazepine-like" in nature. Nonbenzodiazepine pharmacodynamics are almost entirely the same as benzodiazepine drugs, and therefore entail similar benefits, side effects, and risks. Nonbenzodiazepines, however, have dissimilar or different chemical structures, and are unrelated to benzodiazepines on a molecular level. Examples include zopiclone (Imovane), eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem (Ambien). Since the generic names of all drugs of this type start with Z, they are often referred to as Z-drugs. Research on nonbenzodiazepines is new and conflicting. A review by a team of researchers suggests the use of these drugs for people who have trouble falling asleep (but not staying asleep), as next-day impairments were minimal. The team noted that the safety of these drugs had been established, but called for more research into their long-term effectiveness in treating insomnia. Other evidence suggests that tolerance to nonbenzodiazepines may be slower to develop than with benzodiazepines. A different team was more skeptical, finding little benefit over benzodiazepines.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.